Search

Your search keyword '"Giebel P"' showing total 9 results
Start Over Author "Giebel P" Journal leukemia
9 results on '"Giebel P"'

1. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT

Author

Esteve, Jordi, Giebel, Sebastian, Labopin, Myriam, Czerw, Tomasz, Wu, Depei, Volin, Liisa, Socié, Gerard, Yakoub-Agha, Ibrahim, Maertens, Johan, Cornelissen, Jan J., Pigneux, Arnaud, Shimoni, Avichai, Schwerdtfeger, Rainer, Labussière-Wallet, Hélène, Russell, Nigel, Schattenberg, Anton, Chevallier, Patrice, Koza, Vladimir, Foà, Robin, Schmid, Christoph, Peric, Zinaida, Mohty, Mohamad, and Nagler, Arnon

Published
2021
Full Text
View/download PDF

2. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia

Author

Nagler, Arnon, Dholaria, Bhagirathbhai, Labopin, Myriam, Savani, Bipin N., Angelucci, Emanuele, Koc, Yener, Arat, Mutlu, Pioltelli, Pietro, Sica, Simona, Gülbas, Zafer, Tischer, Johanna, Bernasconi, Paolo, Pavlu, Jiri, Socié, Gerard, Blaise, Didier, Rigacci, Luigi, Martino, Massimo, Diez-Martin, Jose Luis, Perić, Zinaida, Giebel, Sebastian, and Mohty, Mohamad

Published
2020
Full Text
View/download PDF

3. Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT

Author

Shem-Tov, Noga, Peczynski, Christophe, Labopin, Myriam, Itälä-Remes, Maija, Blaise, Didier, Labussière-Wallet, Hélène, Socié, Gerard, Kröger, Nicolaus, Mielke, Stephan, Afanasyev, Boris, Chevallier, Patrice, Tischer, Johanna, Helbig, Grzegorz, Jindra, Pavel, Peric, Zinaida, Giebel, Sebastian, Mohty, Mohamad, and Nagler, Arnon

Published
2020
Full Text
View/download PDF

4. GFI1 as a novel prognostic and therapeutic factor for AML/MDS

Author

Hönes, J M, Botezatu, L, Helness, A, Vadnais, C, Vassen, L, Robert, F, Hergenhan, S M, Thivakaran, A, Schütte, J, Al-Matary, Y S, Lams, R F, Fraszscak, J, Makishima, H, Radivoyevitch, T, Przychodzen, B, da Conceição Castro, S V, Görgens, A, Giebel, B, Klein-Hitpass, L, Lennartz, K, Heuser, M, Thiede, C, Ehninger, G, Dührsen, U, Maciejewski, J P, Möröy, T, and Khandanpour, C

Published
2016
Full Text
View/download PDF

6. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

Author

Holowiecki, J, Grosicki, S, Robak, T, Kyrcz-Krzemien, S, Giebel, S, Hellmann, A, Skotnicki, A, Jedrzejczak, W W, Konopka, L, Kuliczkowski, K, Zdziarska, B, Dmoszynska, A, Marianska, B, Pluta, A, Zawilska, K, Komarnicki, M, Kloczko, J, Sulek, K, Haus, O, Stella-Holowiecka, B, Baran, W, Jakubas, B, Paluszewska, M, Wierzbowska, A, Kielbinski, M, and Jagoda, K

Published
2004
Full Text
View/download PDF

8. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT

Author

Esteve, Jordi, Giebel, Sebastian, Labopin, Myriam, Czerw, Tomasz, Wu, Depei, Volin, Liisa, Socié, Gerard, Yakoub-Agha, Ibrahim, Maertens, Johan, Cornelissen, Jan J., Pigneux, Arnaud, Shimoni, Avichai, Schwerdtfeger, Rainer, Labussière-Wallet, Hélène, Russell, Nigel, Schattenberg, Anton, Chevallier, Patrice, Koza, Vladimir, Foà, Robin, Schmid, Christoph, Peric, Zinaida, Mohty, Mohamad, and Nagler, Arnon

Abstract

Adult B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with t(4;11)(q21;q23);KMT2A/AFF1is a poor-prognosis entity. This registry-based study was aimed to analyze outcome of patients with t(4;11) BCP-ALL treated with allogeneic hematopoietic stem cell transplantation (alloHSCT) in first complete remission (CR1) between 2000 and 2017, focusing on the impact of measurable residual disease (MRD) at the time of transplant. Among 151 patients (median age, 38) allotransplanted from either HLA-matched siblings or unrelated donors, leukemia-free survival (LFS) and overall survival (OS) at 2 years were 51% and 60%, whereas relapse incidence (RI) and non-relapse mortality (NRM) were 30% and 20%, respectively. These results were comparable to a cohort of contemporary patients with diploid normal karyotype (NK) BCP-ALL with equivalent inclusion criteria (n= 567). Among patients with evaluable MRD pre-alloHSCT, a negative status was the strongest beneficial factor influencing LFS (hazard ratio [HR] = 0.2, p< 0.001), OS (HR = 0.14, p< 0.001), RI (HR = 0.23, p= 0.001), and NRM (HR = 0.16, p= 0.002), with a similar outcome to MRD-negative NK BCP-ALL patients. In contrast, among patients with detectable pretransplant MRD, outcome in t(4;11) BCP-ALL was inferior to NK BCP-ALL (LFS: 27% vs. 50%, p= 0.02). These results support indication of alloHSCT in CR1 for t(4;11) BCP-ALL patients, provided a negative MRD status is achieved. Conversely, pre-alloHSCT additional therapy is warranted in MRD-positive patients.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results